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Introduction: Tumor-associated trypsin inhibitor (TATI) limits serine proteases, 27 
promotes carcinogenesis in several cancers and functions as an acute-phase reactant. 28 
Tumor-associated trypsin-2 (TAT -2), a proteolytic target enzyme for TATI, can 29 
enhance invasion by promoting extracellular matrix degradation. Here, we aimed to 30 
study serum TATI and TAT-2 levels, including the TAT-2/TATI ratio, as prognostic 31 
and diagnostic biomarkers in gastric cancer. We compared the results with the plasma 32 
level of C-reactive protein (CRP). 33 
 34 
Materials and Methods: We selected 240 individuals operated on for gastric 35 
adenocarcinoma at the Helsinki University Hospital, Finland, between 2000 and 2009. 36 
We determined the preoperative serum TAT-2, TATI and plasma CRP levels using 37 
time-resolved immunofluorometric assays using monoclonal antibodies. 38 
 39 
Results: The medium serum TAT-2 level was higher among gastric cancer patients 40 
[8.68 ng/ml; interquartile range (IQR) 5.93–13.2] than among benign controls (median 41 
5.41 ng/ml; IQR 4.12–11.8; P = 0.005). Five-year survival among patients with a high 42 
serum TAT-2 was 22.9% [95% confidence interval (CI) 11.7–34.1], compared to 52.2% 43 
(95% CI 44.6–59.8; p < 0.001) among those with a low level. The five-year survival 44 
among patients with a high serum TATI was 30.6% (95% CI 20.4–40.8), compared to 45 
52.9% (95% CI 44.7–61.1; P < 0.001) among those with a low level. The serum TATI 46 
level remained significant in the multivariable survival analysis (hazard ratio 2.01; 95% 47 
CI 1.32–3.07). An elevated plasma CRP level associated with a high serum TATI level 48 




Conclusion: This study shows for the first time that a high serum TAT-2 may function 51 
as a prognostic biomarker in gastric cancer and that TAT-2 levels may be elevated 52 
compared to controls. Additionally, we show that the prognosis is worse among gastric 53 
cancer patients with a high serum TATI. These biomarkers serve as prognostic factors 54 
particularly among patients with a metastatic or a locally advanced disease. 55 
 56 
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Gastric adenocarcinoma represents one of the most lethal cancers worldwide [1]. In the 60 
early stages of the disease, symptoms are scarce; when severe symptoms appear, 61 
however, the disease has often already spread. None of the tumor markers currently 62 
clinically available have demonstrated a sufficient sensitivity to be useful for detecting 63 
gastric cancer and carry a limited prognostic value [2]. 64 
 Tumor-associated trypsin inhibitor (TATI), also known as the pancreatic 65 
secretory trypsin inhibitor (PSTI), is a serine protease inhibitor first found in the urine 66 
of a patient with gynecological cancer [3,4], called serine peptidase inhibitor Kazal-type 67 
1 (SPINK1). In addition to inhibiting serine proteases, it appears to promote 68 
carcinogenesis by activating the epidermal growth factor receptors (EGFRs) [5,6]. In 69 
addition to gastric cancer, TATI expresses in several other cancers, including colorectal, 70 
pancreatic, ovarian, bladder, renal, prostate, lung, breast and liver cancers, and appears 71 
useful for both diagnostic and prognostic purposes [6]. The prognostic role of TATI in 72 
gastric cancer remains controversial since, on the one hand, a high TATI expression in 73 
gastric carcinoma tissues served as a marker of a favorable outcome and associated with 74 
a low cancer stage, superficial tumors and the absence of metastasis. On the other hand, 75 
higher serum TATI levels were found more often among gastric cancer patients than 76 
among controls and associated with advanced disease [7,8]. Additionally, TATI acts as 77 
an acute-phase reactant and the regulation of its synthesis resembles that of the C-78 
reactive protein (CRP) and other acute-phase reactants [9,10]. Thus, in addition to 79 
malignant diseases, an elevated serum TATI level may result from an inflammation 80 
caused by an infection or tissue damage [11,12]. 81 
 Tumor-associated trypsin-2 (TAT-2) represents one of the proteolytic target 82 
enzymes for TATI [13]. A high TAT-2 expression enhances a tumor’s invasive capacity 83 
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through increased extracellular matrix degradation via the activation of pro-urokinase 84 
and matrix metalloproteinases [14,15]. Moreover, a surplus of TAT-2 compared to 85 
TATI, leading to a high TAT-2/TATI ratio, may result in increased TAT-2 activity [6]. 86 
Furthermore, TAT-2 expresses in several cancers, including gastric cancer, yet the 87 
background levels of pancreatic secretory trypsin limit its clinical use in diagnosing 88 
pancreatitis [16–19]. In a previous study of serum trypsinogen in gastric cancer patients, 89 
TAT-2 levels were significantly higher among those with a linitis plastica–type gastric 90 
cancer compared to those with a non-linitis plastica–type gastric cancer [20]. Likewise, 91 
trypsin production by gastric cancer cells associates with an increased in vitro 92 
invasiveness of the tumor cells [17,21]. Serum TAT-2 has not been previously studied 93 
in gastric cancer as a prognostic biomarker. 94 
 CRP has been studied in several cancers in attempts to clarify the mechanism 95 
behind the systemic inflammatory reaction sometimes seen in cancer [22]. In colon 96 
cancer, after excluding patients undergoing emergency surgery and those with auto-97 
immune disease or infection, an elevated preoperative CRP predicts a poor outcome 98 
[23]. A high preoperative CRP was also shown to indicate a poor outcome following 99 
surgical resection of pancreatic ductal adenocarcinoma or colorectal liver metastases 100 
[24,25]. Among gastric cancer patients, an elevated preoperative CRP served as a 101 
marker of a poor outcome and associated with metastatic disease [26,27]. Similarly, a 102 
recent meta-analysis consisting of 2597 gastric cancer patients concluded that an 103 
elevated preoperative CRP predicts a poor outcome [28]. 104 
 Here, we aimed to study serum TATI and TAT-2 levels, including the TAT-105 
2/TATI ratio, as prognostic and diagnostic biomarkers in gastric cancer. We also 106 




Materials and Methods 109 
Patients and ethics 110 
Our cohort consisted of 240 patients operated on for gastric adenocarcinoma in the 111 
Department of Surgery, Helsinki University Hospital, Finland, between 2000 and 2009, 112 
as previously described [29]. Patients undergoing surgery were consecutively included 113 
in this study, excluding individuals with a history of malignant disease or synchronous 114 
cancer. Each gastric tumor was histologically verified as gastric adenocarcinoma by an 115 
experienced pathologist from the Department of Pathology. We used the seventh 116 
version of the Tumor-Node-Metastasis (TNM) classification for the cancer staging [30]. 117 
We compared gastric cancer patients to 48 control patients undergoing surgery or 118 
gastroscopy to treat and diagnose a variety of non-malignant conditions between 2000 119 
and 2012 (Supplementary Table 1). 120 
 We updated survival data in August 2019. Data were received from patient 121 
records, the Population Register Center of Finland and Statistics Finland. 122 
 The Surgical Ethics Committee of Helsinki University Hospital (Dnro HUS 123 
226/E6/ 06, extension TMK02 §66 17.4.2013) approved the study protocol. We were 124 
authorized to study the archived tissue samples retrospectively without requiring further 125 
individual consent or permission as issued by the National Supervisory Authority of 126 
Welfare and Health (Valvira Dnro 10041/06.01.03.01/2012).  127 
 128 
Serum and plasma samples 129 
Blood samples were drawn 1 to 30 days (median, 1 day) before surgery. Serum and 130 
plasma were separated, aliquoted and stored at -80°C until analysis, according to the 131 
routine procedures of the hospital laboratory. 132 
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 To determine the gastric cancer patients’ plasma CRP levels, we applied a high-133 
sensitivity method [time-resolved immunofluorometric assay (TR-IFMA) in 134 
microtitration plates using a monoclonal CRP antibody (anti-hCRP, code 6405, Medix 135 
Biochemica, Espoo, Finland)], as detailed elsewhere [24]. The gastric cancer patients’ 136 
serum TATI and TAT-2 levels were also determined using TR-IFMA, which we 137 
described previously [31,32]. 138 
 139 
Statistical analyses 140 
We explored the strength of associations between biomarker levels and 141 
clinicopathological variables among gastric cancer patients using the Mann-Whitney U-142 
test and the Kruskal-Wallis test. Correlations were evaluated using the Spearman’s rank 143 
correlation. We dichotomized the variables for the survival analyses. The cut-off value 144 
for CRP was 10 mg/l. In the survival analyses, cut-off values for TAT-2, TATI, and the 145 
TAT-2/TATI ratio were determined using the maximum value for Youden’s index to 146 
find the best prognostic performance among our cohort of  gastric cancer patients [33]. 147 
Furthermore, validation analyses were conducted using median cut-off values for TAT-148 
2 and TATI (Supplementary Table 4). We determined the significant difference in 149 
biomarker levels between gastric cancer patients and controls using the Mann-Whitney 150 
U-test. Additionally, in studying the diagnostic value of TAT-2, the receiver operating 151 
characteristic (ROC) curve analysis was applied to study the area under the curve and to 152 
determine a distinct cut-off value for TAT-2 to calculate the sensitivity, specificity, 153 
predictive values, and accuracy. The cut-off value was determined by the maximum 154 
value of Youden’s index to optimally differentiate gastric cancer patients from controls, 155 
with equal values for sensitivity and specificity. The Kaplan-Meier method was applied 156 
to create survival curves, and the statistical significance was calculated using the log-157 
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rank test. We used the Cox proportional hazard model to calculate the hazard ratios 158 
(HRs) for the uni- and multivariable survival analyses. Covariates entered into the 159 
multivariable survival analysis consisted of age, stage, the Laurén classification and the 160 
serum TAT-2 and TATI levels. Cancer stage was processed as a categorical covariate, 161 
in which we compare patients with higher cancer stages to those with stage I cancer. 162 
Furthermore, we studied gastric cancer patients’ survival in several subgroups using the 163 
Cox proportional hazard model and visually depicted it using the Kaplan-Meier 164 
estimators. The patient subgroups analyzed were stratified by age, gender, TNM-165 
classification, stage, the Laurén classification, and the CRP, TAT-2, and TATI levels. 166 
The primary outcome in all of the survival analyses was death due to gastric cancer. We 167 
calculated the disease-specific survival from the date of surgery to the end of follow-up 168 
or death due to gastric cancer. Individuals leaving the study before the end of follow-up 169 
and individuals dying of causes other than gastric cancer were censored. We considered 170 
a two-tailed P-value of less than 0.05 as statistically significant across all analyses. We 171 
used IBM’s SPSS Statistics for Mac version 24.0 (IBM Corporation, Armonk, NY, 172 
USA) for all analyses. 173 
 174 
Results 175 
Diagnostic value of TAT-2, TATI, TAT-2/TATI ratio and 176 
CRP 177 
Serum TAT-2 levels were higher among gastric cancer patients [median 8.68 ng/ml; 178 
interquartile range (IQR) 5.93–13.2] than controls (median 5.41 ng/ml; IQR 4.12–11.8; 179 
P = 0.005; Supplementary Table 2). The area under the ROC curve was 0.63 (95% CI 180 
0.53–0.72; P = 0.005). The maximum value of Youden’s index was used to determine 181 
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the optimal cut-off value (5.45 ng/ml) for TAT-2 to calculate the sensitivity, specificity, 182 
predictive values and accuracy among gastric cancer patients and controls. The 183 
sensitivity of TAT-2 to distinguish gastric cancer patients from controls reached 78.3% 184 
with a specificity of 52.1%. The positive predictive value reached 89.1%, with a 185 
negative predictive value of 32.5% and an accuracy of 74.0%. The prevalence of gastric 186 
cancer in this test population reached 83.3%. We found no significant differences in the 187 
TATI or CRP levels or in the TAT-2/TATI ratio between gastric cancer patients and 188 
controls. 189 
 190 
Associations between TAT-2, TATI, TAT-2/TATI ratio, CRP 191 
and clinicopathological variables 192 
We found statistically significant associations between a high serum TAT-2 level and 193 
pT3–4 tumors (P = 0.046) and between high serum TAT-2 and TATI levels (P < 0.001; 194 
Table 1). We also identified statistically significant associations between a high serum 195 
TATI and an older age (P = 0.001), between a high serum TATI and pT3–4 tumors (P = 196 
0.030) and between a high serum TATI and an elevated CRP (P = 0.037). Furthermore, 197 
we discovered statistically significant associations between a high serum TAT-2/TATI 198 
ratio and diffuse-type tumors (P = 0.004) and between a high serum TAT-2/TATI ratio 199 
and a younger age (P < 0.001; Supplementary Table 3). We also identified a positive 200 
correlation between the TAT-2 and TATI levels (rs 0.438; P < 0.001). 201 
 Plasma CRP was elevated among older patients (P = 0.024), patients with pT3–4 202 
tumors (P = 0.047) and among patients with intestinal-type tumors (P = 0.006; 203 
Supplementary Table 3). We found no other statistically significant associations 204 
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between the studied biomarkers and the clinicopathological variables. [Table 1 near 205 
here] 206 
 207 
Survival analyses 208 
Optimal cut-off values for the survival analyses for TAT-2, TATI and the TAT-2/TATI 209 
ratio were determined using the maximum value for Youden’s index (for TAT-2, 12.91 210 
ng/ml; for TATI, 18.76 ng/ml; and for the TAT-2/TATI ratio, 0.58). Five-year disease-211 
specific survival among patients with a high serum TAT-2 was 22.9% [95% confidence 212 
interval (CI) 11.7–34.1], and 52.2% among patients with a low TAT-2 (95% CI 44.6–213 
59.8; P < 0.001; Table 2; Figure 1A). The five-year survival among patients with a high 214 
serum TATI was 30.6% (95% CI 20.4–40.8), and 52.9% among patients with a low 215 
TATI (95% CI 44.7–61.1; P < 0.001; Figure 1B). The serum TAT-2/TATI ratio or 216 
plasma CRP did not function as significant prognostic factors in the whole cohort. 217 
 Serum TATI remained an independent prognostic factor in the multivariable 218 
survival analysis [hazard ratio (HR) 2.01; 95% CI 1.32–3.07; Table 2]. Other significant 219 
prognostic factors in the multivariable survival analysis included age, stage and 220 
histological type according to the Laurén classification. No significant interaction terms 221 
were identified in the final model. [Table 2 and Figure 1 near here] 222 
 223 
Survival analyses by subgroups 224 
Among patients with pT3–4 tumors, a high TAT-2 level (Figure 1C) and a high TATI 225 
level (Table 3; Figure 1D) served as markers of a poor outcome. A high TAT-2 level 226 
served as a marker for an adverse outcome among those with a low TATI level (Figure 227 
1E). Similarly, a high TATI level served as a marker for a poor outcome among those 228 
with a low TAT-2 level (Figure 1F). 229 
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 Furthermore, a high TAT-2 level served as a marker for a poor outcome among 230 
those with lymph-node metastasis and among those without lymph-node metastasis 231 
(Table 3; Figure 2A). Correspondingly, a high TATI level served as a marker for a poor 232 
outcome among those with lymph-node metastasis and among those without lymph-233 
node metastasis (Figure 2B). A high TAT-2 level emerged as indicative of a poor 234 
outcome among those with either intestinal- or diffuse-type tumors (Figure 2C). 235 
Likewise, a high TATI level served as a marker for a poor outcome among those with 236 
either intestinal- or diffuse-type tumors (Figure 2D). A high TAT-2 level served as a 237 
marker for a poor outcome among those with an elevated CRP (Figure 2E) and among 238 
those without an elevated CRP. Similarly, a high TATI level served as a marker for a 239 
poor outcome among those with an elevated CRP (Figure 2F) and among those without 240 
an elevated CRP. Additionally, TAT-2 and TATI served as prognostic biomarkers in 241 
several other subgroups presented in Table 3. 242 
 A high TAT-2/TATI ratio served as a marker for a poor outcome among older 243 
patients (HR 2.26; 95% CI 1.39–3.67). [Table 3 and Figure 2 near here] 244 
 245 
Discussion 246 
Here, we show that, in our cohort of 240 gastric adenocarcinoma patients, high serum 247 
TAT-2 and TATI levels function as markers for a poor outcome. Both parameters are 248 
promising prognostic biomarkers, although only TATI remained significant in the 249 
multivariable survival analysis, suggesting its prognostic value is superior to that of 250 
TAT-2 in this patient cohort. Nevertheless, to our knowledge, this is the first time that 251 
serum TAT-2 has been identified as a prognostic biomarker in gastric cancer. 252 
Additionally, we show that the expression levels of these biomarkers correlate 253 
positively with gastric cancer. Neither the TAT-2/TATI ratio nor CRP functioned as 254 
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prognostic biomarkers in this study. Furthermore, we evaluated the biomarkers’ 255 
diagnostic properties, demonstrating that serum TAT-2 levels were higher among 256 
gastric cancer patients than among benign controls. 257 
 High serum TAT-2 and TATI levels predicted an unfavorable outcome in 258 
several of the subgroups we studied. Interestingly, they did not function as prognostic 259 
factors among patients with pT1–2 tumors or with stage I, II or III disease, but among 260 
those with pT3–4 tumors or stage IV disease. Because high TAT-2 and TATI levels 261 
were also associated with pT3–4 tumors, the mechanisms via which a high level of 262 
TAT-2 or TATI affect disease progression appear important in locally advanced or 263 
metastatic disease rather than in early-stage gastric cancer. Specifically, TAT-2 264 
enhances the tumor’s invasive abilities via the increased degradation of the extracellular 265 
matrix through the activation of pro-urokinase and matrix metalloproteinases. TATI, 266 
furthermore, promotes tumor growth via the activation of EGFRs. In a clinical setting, 267 
our results agree with previous studies [6,14,15]. However, because TAT-2 and TATI 268 
also functioned as prognostic factors among patients without lymph-node or distant 269 
metastases, their roles in gastric cancer carcinogenesis do not appear limited to the 270 
pathogenesis of advanced disease. 271 
 This study further clarifies the role of TATI in gastric cancer, as previously 272 
described, as associating, on the one hand, with advanced disease and, on the other 273 
hand, associating with a favorable outcome and the absence of metastasis [7,8]. A high 274 
tissue expression of TATI was previously found to associate with a favorable prognosis, 275 
superficial tumors and the absence of lymph-node and distant metastases [7]. Yet, in 276 
this study, we found a high serum TATI associated with an adverse prognosis and with 277 
locally advanced disease. It, thus, seems that in gastric cancer the expression of TATI 278 
may affect disease progression differently depending upon whether it circulates in the 279 
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plasma or is expressed in the tumor tissue. TATI was previously studied in the sera of 280 
gastric cancer patients yielding results similar to ours, whereby a high serum level 281 
associated with locally advanced disease [8]. In that study, survival was not analyzed, 282 
although a high TATI level associated with metastasis, indicative of a poor outcome 283 
among patients with high TATI levels. Furthermore, in that study, statistically 284 
significant differences in the serum TATI levels between gastric cancer patients and 285 
controls were found, which we did not find here. The discrepancy between these results 286 
may be explained by the choice of controls. We selected controls with benign disease, 287 
whereas the previous study relied on healthy individuals. 288 
 The expression of trypsinogen using gastric cancer cells was previously shown 289 
to associate with invasive growth [17,21]. Here, we showed in a clinical setting that a 290 
high serum TAT-2 associated with pT3–4 gastric tumors and a poor outcome, providing 291 
evidence of TAT-2’s importance in tumor invasion. Similarly, gastric cancer patients’ 292 
high serum trypsinogen levels were previously shown to associate with a linitis 293 
plastica–type cancer, known for its poor prognosis due to its extremely invasive method 294 
of growth [20].  295 
 TATI and CRP both function as acute-phase reactants, whereby regulating their 296 
synthesis was described as resembling that of each other [9,10]. Similarly, we 297 
discovered that among gastric cancer patients an elevated CRP and a high TATI level 298 
associate with each other. Interestingly, the hazard ratios among patients with high 299 
TATI or TAT-2 levels compared to those with low TATI or TAT-2 levels were higher if 300 
CRP was elevated. Thus, in patients with a systemic inflammatory response, the 301 
mechanisms via which TAT-2 and TATI may affect patient survival appear amplified. 302 
 In this study, CRP did not function as a prognostic biomarker nor did we detect 303 
differences in the CRP levels between gastric cancer patients and controls. However, 304 
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similar to previous studies, we identified an elevated CRP as associated with locally 305 
advanced disease [26,27]. A recent meta-analysis of 2597 gastric cancer patients 306 
concluded that a high preoperative CRP level predicts a poor outcome. Yet, in 3 of the 307 
12 original studies included in that meta-analysis, CRP failed to function as a prognostic 308 
marker, mirroring findings from our study [28]. To understand why studies of CRP as a 309 
prognostic biomarker among similar gastric cancer patient cohorts with similar 310 
laboratory and statistical methodologies continue to yield conflicting results, further 311 
studies on other large, well-defined patient cohorts and further meta-analysis are 312 
necessary. We previously showed that plasma CRP, determined using similar methods, 313 
functions as a prognostic factor among pancreatic cancer patients, suggesting that the 314 
non-significance in this study does not result from an erroneous analysis [24]. 315 
 Whether or not these two serum markers could be applied in clinical practice in 316 
the future remains difficult to determine definitively. Perhaps patients with pT3–4 317 
tumors and high levels of TAT-2 and TATI could benefit from more dose-intensive 318 
perioperative chemotherapy or more frequent follow-up. Furthermore, patients with a 319 
limited metastatic disease and low TAT-2 and TATI levels could potentially serve as 320 
candidates for curative surgical treatment in addition to chemotherapy. Nevertheless, 321 
these two parameters remain candidates for further exploration among patients with 322 
gastric cancer. 323 
 The strengths of this study include the large patient cohort with a long follow-up 324 
period consisting of reliable outcome and survival information. The single-center setting 325 
limits the generalizability of our findings, and several individual subgroup analyses 326 
were conducted in this study, possibly predisposing the results to familywise errors. 327 
Cut-off values calculated using Youden’s index provide high segregation performance 328 
in this patient cohort and cannot be generalized as such. Our results should be validated 329 
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in independent patient cohorts, preferably in a multi-center setting. We chose not to 330 
include certain well-known risk factors for gastric cancer, such as tumor subsite, 331 
perineural and venous invasion and lymphatic emboli in the analyses, since accessing 332 
these data in a retrospective manner could introduce inaccuracies. Furthermore, we lack 333 
appropriate and detailed data on the chemotherapy administered.  334 
 In conclusion, this study shows for the first time that a high serum TAT-2 may 335 
function as a prognostic biomarker in gastric cancer and that TAT-2 levels may be 336 
elevated compared to controls. Additionally, we show that the prognosis is worse 337 
among gastric cancer patients with a high serum TATI. These biomarkers serve as 338 
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Figure legends 451 
Figure 1. Gastric cancer patients’ disease-specific survival according to the 452 
Kaplan-Meier method. P-values were calculated according to the log-rank test. Low  453 
versus high A) TAT-2 and B) TATI across the entire cohort. Low versus high C) TAT- 454 
2 and D) TATI among patients with pT3–4 tumors. E) Low versus high TAT-2 among  455 
patients with a low TATI and F) low versus high TATI among patients with a low  456 
TAT-2. 457 
 458 
Figure 2. Gastric cancer patients’ disease-specific survival stratified by subgroups 459 
according to the Kaplan-Meier method. P-values were calculated according to the log-460 
rank test. Low versus high A) TAT-2 and B) TATI among patients with lymph-node 461 
metastasis (red lines) and among patients without lymph-node metastasis (black lines). 462 
Low versus high C) TAT-2 and D) TATI among patients with intestinal- (red lines) and 463 
diffuse-type (black lines) tumors. Low versus high E) TAT-2 and F) TATI among 464 
patients with elevated CRP levels.  465 
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Table 1. Association of serum TAT-2 and TATI with the clinicopathologic variables 466 
and CRP among 240 gastric cancer patients. 467 
        
 Serum TAT-2 (ng/ml)  Serum TATI (ng/ml) 
 Median IQR P value  Median IQR P value 
        
        
Age, years        
<67 8.95 6.59–12.9 0.1741  14.0 11.0–20.7 0.0011 
≥67 8.10 5.17–14.05   18.2 12.1–27.4  
        
Gender        
Male 9.21 5.85–15.3 0.1711  16.1 11.3–24.6 0.4871 
Female 8.11 5.91–11.3   15.7 10.8–22.2  
        
Stage        
I 8.39 5.25–11.8 0.5852  13.4 10.5–20.1 0.2842 
II 8.89 6.39–13.1   18.0 11.6–26.5  
III 8.56 5.46–12.9   15.7 11.2–23.9  
IV 9.10 6.60–18.5   16.0 11.3–23.4  
        
Tumor classification (pT)        
pT1–2 7.76 5.00–11.1 0.0461  13.8 10.6–20.0 0.0301 
pT3–4 9.07 6.30–14.3   16.3 11.6–24.6  
        
Lymph node metastasis (pN)        
pN0 8.79 6.31–12.4 0.6021  16.0 10.6–23.5 0.4791 
pN1–3 8.56 5.33–13.3   16.0 11.3–23.6  
        
Distant metastasis (pM)        
pM0 8.59 5.64–12.7 0.1751  15.9 11.2–23.6 0.8931 
pM1 9.10 6.60–18.5   16.0 11.3–23.4  
        
Laurén classification        
Intestinal 7.89 5.30–12.7 0.0881  17.7 11.7–26.5 0.0641 
Diffuse 9.17 6.33–14.0   15.3 10.8–22.0  
        
CRP        
<10 8.76 5.88–13.1 0.5231  15.7 11.1–22.4 0.0371 
≥10 8.59 6.40–18.3   19.2 13.0–30.0  
        
Serum TAT-2        
Low     14.2 10.6–18.6 <0.0011 
High     24.6 17.7–34.3  
        
Serum TATI        
Low 7.47 4.97–10.3 <0.0011     
High 13.2 8.10–21.3      
        
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin 468 
inhibitor, CRP = C-reactive protein, IQR = interquartile range 469 
1Mann-Whitney U-test, 2Kruskal-Wallis test  470 
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Table 2. Uni- and multivariable survival analyses for 240 gastric cancer patients. 471 
Disease-specific survival was analyzed. 472 
      
 Univariable  Multivariable 
 HR 95% CI  HR 95% CI 
       
      
Age, years      
<67 1.00   1.00  
≥67 1.44 1.07–1.94  2.32 1.61–3.33 
      
Stage      
I 1.00   1.00  
II 4.97 2.05–12.0  6.10 2.08–17.8 
III 14.8 6.46–34.0  23.0 8.32–63.5 
IV 41.7 17.7–98.1  87.8 30.1–256 
      
Laurén classification      
Intestinal 1.00   1.00  
Diffuse 1.45 1.06–1.98  2.50 1.67–3.74 
      
CRP      
<10 1.00     
≥10 1.29 0.83–1.98    
      
Serum TAT-2      
Low 1.00   1.00  
High 1.93 1.35–2.76  1.27 0.83–1.95 
      
Serum TATI      
Low 1.00   1.00  
High 1.84 1.31–2.57  2.01 1.32–3.07 
      
Serum TAT-2/TATI ratio      
Low 1.00     
High 1.27 0.91–1.77    
       
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin 473 
inhibitor, CRP = C-reactive protein, HR = hazard ratio, CI = confidence interval  474 
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Table 3. Survival analyses by subgroups, high serum TAT-2 and TATI levels compared 475 
to low among 240 gastric cancer patients. Disease-specific survival was analyzed. 476 
      
 High Serum TAT-2  High Serum TATI 
 HR 95% CI  HR 95% CI 
       
      
Age, years      
<67 1.66 0.99–2.76  1.63 1.00–2.68 
≥67 2.24 1.35–3.70  1.86 1.15–3.02 
      
Gender      
Male 1.87 1.13–3.11  1.80 1.09–2.97 
Female 2.12 1.27–3.55  1.87 1.19–2.96 
      
Stage      
I 4.73 0.66–33.6  3.48 0.48–25.1 
II 2.24 0.90–5.59  1.68 0.71–3.97 
III 1.42 0.85–2.38  2.13 1.33–3.41 
IV 2.25 1.15–4.41  2.37 1.12–4.62 
      
Tumor classification (pT)      
pT1–2 0.97 0.22–4.35  1.42 0.44–4.54 
pT3–4 1.70 1.17–2.47  1.57 1.10–2.23 
      
Lymph node metastasis (pN)      
pN0 3.28 1.27–8.50  3.56 1.38–9.23 
pN1–3 1.61 1.08–2.42  1.81 1.24–2.65 
      
Distant metastasis (pM)      
pM0 1.73 1.12–2.67  1.94 1.31–2.89 
pM1 2.25 1.15–4.41  2.37 1.21–4.62 
      
Laurén classification      
Intestinal 2.19 1.05–4.57  2.10 1.10–4.02 
Diffuse 1.76 1.17–2.66  1.86 1.25–2.78 
      
CRP      
<10 1.65 1.10–2.47  1.67 1.14–2.44 
≥10 3.67 1.64–8.22  2.51 1.08–5.84 
      
Serum TAT-2      
Low    1.80 1.15–2.83 
High    1.02 0.52–2.02 
      
Serum TATI      
Low 2.30 1.21–4.36    
High 1.25 0.75–2.08    
       
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin 477 
inhibitor, CRP = C-reactive protein, HR = hazard ratio, CI = confidence interval 478 
Supplementary Table 1. Indications for surgery or gastroscopy among the 48 control patients.
Indication Count
Peptic ulcer disease 12






Other non-malignant disease 4
Supplementary Table 2. Serum TAT-2, TATI, TAT-2/TATI ratio, and CRP among gastric cancer patients
versus controls.
Median IQR Median IQR P value1
TAT-2 (ng/ml) 8.68 5.93–13.2 5.41 4.12–11.8 0.005
TATI (ng/ml) 15.9 11.2–23.5 14.5 10.3–20.1 0.357
TAT-2/TATI ratio 0.55 0.36–0.86 0.46 0.26–0.78 0.063
CRP (mg/l) 1.62 0.51–5.81 2.04 0.42–8.44 0.627
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin inhibitor,
CRP = C-reactive protein, IQR = interquartile range
1Mann-Whitney U-test
Gastric Cancer Controls
Supplementary Table 3. Association of CRP and TAT-2/TATI ratio with clinicopathologic variables among 240 gastric cancer
patients.
Median IQR P value Median IQR P value
Age, years
<67 1.12 0.48–3.49 0.0241 0.64 0.41–1.04 <0.0011
≥67 2.19 0.56–7.80 0.45 0.33–0.67
Gender
Male 1.75 0.66–5.52 0.2651 0.57 0.36–0.91 0.4131
Female 1.40 0.39–5.98 0.53 0.35–0.83
Stage
I 1.07 0.41–5.43 0.3362 0.55 0.39–0.98 0.2672
II 1.58 0.40–3.38 0.47 0.31–0.78
III 1.62 0.65–5.83 0.55 0.35–0.79
IV 2.81 0.51–10.0 0.59 0.38–1.11
Tumor classification (pT)
pT1–2 1.12 0.41–4.32 0.0471 0.54 0.36–0.81 0.8381
pT3–4 1.84 0.61–7.77 0.55 0.35–0.88
Lymph node metastasis (pN)
pN0 1.33 0.41–4.54 0.3911 0.54 0.37–0.88 0.4941
pN1–3 1.73 0.56–6.24 0.55 0.34–0.79
Distant metastasis (pM)
pM0 1.48 0.54–4.90 0.1221 0.54 0.35–0.81 0.1781
pM1 2.81 0.51–10.0 0.59 0.38–1.11
Laurén classification
Intestinal 2.75 0.88–7.65 0.0061 0.48 0.33–0.71 0.0041
Diffuse 1.15 0.41–5.30 0.61 0.39–0.98
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin inhibitor,
CRP = C-reactive protein, IQR = interquartile range
1Mann-Whitney U-test, 2Kruskal-Wallis test
CRP (mg/l) Serum TAT-2/TATI ratio
Supplementary Table 4. Univariable survival analyses with median cut-off values for TAT-2 and TATI.








Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin inhibitor,
HR = hazard ratio, CI = confidence interval
Table 1. Association of serum TAT-2, TATI, and TAT-2/TATI ratio with clinicopathologic variables and CRP among 240 gastric cancer patients.
Median IQR P value Median IQR P value
Age, years
<67 8.95 6.59–12.9 0.1741 14.0 11.0–20.7 0.0011
≥67 8.10 5.17–14.05 18.2 12.1–27.4
Gender
Male 9.21 5.85–15.3 0.1711 16.1 11.3–24.6 0.4871
Female 8.11 5.91–11.3 15.7 10.8–22.2
Stage
I 8.39 5.25–11.8 0.5852 13.4 10.5–20.1 0.2842
II 8.89 6.39–13.1 18.0 11.6–26.5
III 8.56 5.46–12.9 15.7 11.2–23.9
IV 9.10 6.60–18.5 16.0 11.3–23.4
Tumor classification (pT)
pT1–2 7.76 5.00–11.1 0.0461 13.8 10.6–20.0 0.0301
pT3–4 9.07 6.30–14.3 16.3 11.6–24.6
Lymph node metastasis (pN)
pN0 8.79 6.31–12.4 0.6021 16.0 10.6–23.5 0.4791
pN1–3 8.56 5.33–13.3 16.0 11.3–23.6
Distant metastasis (pM)
pM0 8.59 5.64–12.7 0.1751 15.9 11.2–23.6 0.8931
pM1 9.10 6.60–18.5 16.0 11.3–23.4
Laurén classification
Intestinal 7.89 5.30–12.7 0.0881 17.7 11.7–26.5 0.0641
Diffuse 9.17 6.33–14.0 15.3 10.8–22.0
CRP
<10 8.76 5.88–13.1 0.5231 15.7 11.1–22.4 0.0371
≥10 8.59 6.40–18.3 19.2 13.0–30.0
Serum TAT-2
Low 14.2 10.6–18.6 <0.0011
High 24.6 17.7–34.3
Serum TATI
Low 7.47 4.97–10.3 <0.0011
High 13.2 8.10–21.3
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin inhibitor, CRP = C-reactive protein, IQR = interquartile range
Serum TAT-2 (ng/ml) Serum TATI (ng/ml)
Table 2. Uni- and multivariate survival analyses for 240 gastric cancer patients.
HR 95% CI P value HR 95% CI P value
Age, years
<67 1.00 1.00
≥67 1.44 1.07–1.94 0.015 2.32 1.61–3.33 <0.001
Stage
I 1.00 1.00
II 4.97 2.05–12.0 <0.001 6.10 2.08–17.8 0.001
III 14.8 6.46–34.0 <0.001 23.0 8.32–63.5 <0.001
IV 41.7 17.7–98.1 <0.001 87.8 30.1–256 <0.001
Laurén classification
Intestinal 1.00 1.00
Diffuse 1.45 1.06–1.98 0.020 2.50 1.67–3.74 <0.001
CRP
<10 1.00
≥10 1.29 0.83–1.98 0.256
Serum TAT-2
Low 1.00 1.00
High 1.93 1.35–2.76 <0.001 1.27 0.83–1.95 0.274
Serum TATI
Low 1.00 1.00
High 1.84 1.31–2.57 <0.001 2.01 1.32–3.07 0.001
Serum TAT-2/TATI ratio
Low 1.00
High 1.27 0.91–1.77 0.161
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin inhibitor,
CRP = C-reactive protein, HR = hazard ratio, CI = confidence interval
Univariate  survival analysis Multivariate  survival analysis
Table 3. Survival analyses by subroups, high serum TAT-2, TATI, and TAT-2/TATI ratio compared to low
among 240 gastric cancer patients.
HR 95% CI P value HR 95% CI P value
Age, years
<67 1.66 0.99–2.76 0.053 1.63 1.00–2.68 0.052
≥67 2.24 1.35–3.70 0.002 1.86 1.15–3.02 0.012
Gender
Male 1.87 1.13–3.11 0.015 1.80 1.09–2.97 0.023
Female 2.12 1.27–3.55 0.004 1.87 1.19–2.96 0.007
Stage
I 4.73 0.66–33.6 0.121 3.48 0.48–25.1 0.217
II 2.24 0.90–5.59 0.083 1.68 0.71–3.97 0.235
III 1.42 0.85–2.38 0.186 2.13 1.33–3.41 0.002
IV 2.25 1.15–4.41 0.018 2.37 1.12–4.62 0.012
Tumor classification (pT)
pT1–2 0.97 0.22–4.35 0.971 1.42 0.44–4.54 0.557
pT3–4 1.70 1.17–2.47 0.005 1.57 1.10–2.23 0.013
Lymph node metastasis (pN)
pN0 3.28 1.27–8.50 0.014 3.56 1.38–9.23 0.009
pN1–3 1.61 1.08–2.42 0.021 1.81 1.24–2.65 0.002
Distant metastasis (pM)
pM0 1.73 1.12–2.67 0.014 1.94 1.31–2.89 0.001
pM1 2.25 1.15–4.41 0.018 2.37 1.21–4.62 0.012
Laurén classification
Intestinal 2.19 1.05–4.57 0.037 2.10 1.10–4.02 0.025
Diffuse 1.76 1.17–2.66 0.007 1.86 1.25–2.78 0.002
CRP
<10 1.65 1.10–2.47 0.015 1.67 1.14–2.44 0.008
≥10 3.67 1.64–8.22 0.002 2.51 1.08–5.84 0.033
Serum TAT-2
Low 1.80 1.15–2.83 0.010
High 1.02 0.52–2.02 0.945
Serum TATI
Low 2.30 1.21–4.36 0.011
High 1.25 0.75–2.08 0.386
Abbreviations: TAT-2 = tumor associated trypsin-2, TATI = tumor associated trypsin inhibitor,
CRP = C-reactive protein, HR = hazard ratio, CI = confidence interval
High Serum TAT-2 High Serum TATI


